OHLCX Market Research
Delayed

BIIB

Biogen specializes in the development of therapies for neurological diseases, including multiple sclerosis and Alzheimer’s.

+2.15 (+0.87%) Nov 20, 2026 19:42 ET Delayed
Open
247.82
High
253.00
Low
247.82
Prev close
247.13
Volume
1M
Avg vol 10
1M

Today · Market closed · opens Mon 9:30 AM

Price

BIIB chart

Updating chart…

Scroll or pinch to zoom, drag to pan, or use the buttons on the chart. About the price history

Signals

Technical analysis

Daily bars · last bar Nov 20, 2026 · close 249.28

Strong sellNeutralStrong buy
Buy
score +0.17 · 18 signalling
6Buy
9Neutral
3Sell

Leaning buy. 6 of 18 signals point up against 3 down, carried by trend and volume. Momentum is mostly neutral. Volatility is mostly neutral. Stoch RSI sits in oversold territory.

How to read this →

Trend

MACD 12, 26, 9
Below signal line, still above zero
MACD 3.60 · Signal 4.91 · Hist −1.31
Sell
ADX 14
Developing trend, +DI slightly ahead
ADX 22.56 · +DI 17.67 · −DI 16.56
Buy
Parabolic SAR 0.02, 0.2
Below price, 6.15 under the close
243.13
Buy
Ichimoku 9, 26, 52
Price above cloud, conversion above base
Conv 249.50 · Base 246.02 · A 226.66 · B 220.46
Buy

Momentum

RSI 14
Mid-range, no extreme
53.73
Neutral
Stoch 14, 3
Mid-range, %K just crossed over %D
%K 44.19 · %D 44.16
Neutral
Stoch RSI 14, 14, 3, 3
Oversold, %K still below %D
%K 13.50 · %D 16.94
Neutral
Williams %R 14
Mid-range, still rising
−55.81
Neutral
CCI 14
Negative, above −100
−23.39
Neutral
MFI 14
Below midpoint, not oversold
31.63
Neutral
ROC 12
Price down 2.04% over 12 bars
−2.04%
Sell
AO 5, 35
Above zero, falling
7.18
Neutral
TRIX 18
Above zero
0.329
Buy
KST 10/15/20/30, 3
Below its signal line
KST 68.99 · Signal 75.08
Sell

Volatility

Bollinger 20, 2
Lower half, %b 0.39
Up 256.74 · Mid 250.63 · Low 244.53
Neutral
Keltner 20, 10, 1.5
Inside the channel, upper half
Up 258.93 · Mid 248.32 · Low 237.70
Neutral

Volume

VWAP 345-bar
Close 38.2% above VWAP
180.41
Buy
Force Index 1
Positive, buyers in control
2.4M
Buy
ATR
7.20
2.89% of close
A/D Line
17.6M
cumulative
OBV
50.5M
cumulative
Volume Profile
171.03 – 181.03
POC · bull 67.0M · bear 43.7M · 61 / 39
Risk and return

Performance

Daily returns for Jan 1, 2026 – Nov 22, 2026 (YTD). About the returns · About the risk figures

1 month return

-1.67%

Change in value over the past month.

3 month return

14.43%

Change in value over the last three months.

Max drawdown

14.34%

Largest fall from a peak to the low that followed.

Standard deviation

35.18%

How far daily returns stray from their average, annualised.

Sharpe ratio

1.26

Return above the risk-free rate per unit of volatility.

Calmar ratio

3.09

Annualised return against the maximum drawdown.

About

BIIB summary

Loading summary…

Questions

BIIB, answered

What are the challenges Biogen faces in the market?

Biogen faces challenges such as competition from other pharmaceutical companies and regulatory hurdles in drug approval processes.

How does Biogen approach drug development?

Biogen employs a rigorous approach, utilizing clinical trials and research to ensure safety and efficacy before launching new treatments.

What role does innovation play in Biogen’s strategy?

Innovation is central to Biogen’s strategy, focusing on developing new therapies to address unmet medical needs in neurology.

What are some key products from Biogen?

Key products include Tecfidera, Avonex, and Spinraza, which are used for various neurological conditions.

How can investors track Biogen’s performance?

Investors can track Biogen’s performance through financial news platforms, stock market apps, and Biogen’s investor relations page.

What recent developments has Biogen announced?

Recent developments include new clinical trial results and potential product launches; for the latest updates, check their press releases.

Is Biogen involved in any partnerships?

Yes, Biogen often collaborates with academic institutions and other companies for research and development purposes.

What is the impact of clinical trial results on Biogen?

Positive clinical trial results can lead to stock price increases and greater market confidence in Biogen’s products.

How can I invest in Biogen?

You can invest in Biogen by purchasing shares through a brokerage account or investing in funds that include Biogen in their portfolio.

How does Biogen research impact the healthcare industry?

Biogen’s research contributes to advancements in treating complex neurological disorders, impacting patient care and treatment options.

News

BIIB in the news

Enhance Your BIIB Trading Now

Maximize your trading efficiency with ohlcx.com. Our advanced trading system provides detailed insights and actionable strategies for BIIB. Don’t wait—Boost your investment success with us and see how our platform can help you achieve your trading goals!

Enhance Your Trading Now

Disclaimers

The information displayed on this site is sourced from third-party providers and is believed to be reliable. OHLCX has not independently verified this data and does not guarantee its accuracy. Content is for educational and informational purposes only and is not financial or investment advice.

With any investment, your capital is at risk. Past performance is no guarantee of future results. Consult your provider's terms and privacy policies where applicable.

Prices, charts and every figure derived from them are delayed by at least 15 minutes and are provided for information only; we do not guarantee their accuracy or timeliness.

Securities products are: Not FDIC insured · Not bank guaranteed · May lose value

Trademarks and logos are the property of their respective owners and do not represent endorsements of any kind.